All posts tagged "leronlimab"

• 

  1.2K

  Biotech

  COVID Stocks Popping in Sympathy with Positive Humanigen Top Line Data

  Humanigen Inc. (NASDAQ: HGEN) released excellent news that their drug lenzilumab improved survival without the need for invasive mechanical ventilation (IMV) by...

• 

  2.3K

  3

  Biotech

  CytoDyn Saves Lives & Reduces COVID-19 Hospital Duration

  6 endpoints met after full data release so shorts double down on trial failure narrative  Investors in CytoDyn Inc. (OTCMKTS: CYDY) are...

• 

  12.7K

  Biotech

  RISE of the COVID-19 Therapeutics CytoDyn (OTCMKTS: CYDY) & Humanigen (NASDAQ:HGEN)

  Enrollment Key Metric in Therapeutic Race Philippines EUA Relevant to CytoDyn, not Humanigen Highly Credentialed Humanigen Team Possibility of NASDAQ Uplisting for...

• 

  12.7K

  1

  Biotech

  CytoDyn (OTCMKTS: CYDY) Subtly Signals Pivot Into Philippines and Vaccine Market

  On Sunday Night CytoDyn Inc. (OTCMKTS:CYDY) quietly placed a link in their developing news section to a 2016 medical journal article that...

• 

  10.9K

  Biotech

  Handicapping CytoDyn’s (OTCMKTS: CYDY) Interim Readout

  Powerful recommendation from DSMB Imminent on Leronlimab Numbers are not part of any Interim report unless a statistical penalty is taken  A...

• 

  10.7K

  1

  Biotech

  All Eyes On CytoDyn Now That Trump Has COVID-19

  Just now, markets are waking up to the news that President Donald Trump and First Lady Melanie have tested positive for COVID-19....

• 

  24.8K

  1

  Biotech

  CytoDyn (OTCMKTS:CYDY) May Make the White House Podium

  CytoDyn Inc. (OTCMKTS:CYDY) may be the target of a White House press briefing very soon. A couple of social media influencers like...

• 

  16.8K

  2

  Biotech

  Wading through the STAT News FUD Attack on CytoDyn Inc. (OTCMKTS: CYDY)

  CytoDyn Inc. (OTCMKTS: CYDY) announced superb top-line data in their mild to moderate COVID-19 phase 2 trial and did not disappoint; however,...

• 

  30.2K

  1

  Biotech

  CytoDyn’s (OTCMKTS: CYDY) Strong Safety Data in Mild to Moderate Smokes Gilead (NASDAQ: GILD) & Crushes Endpoint Leading to the First Potential COVID-19 Approval

  CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today.  The company reported a...

• 

  13.5K

  1

  Biotech

  CytoDyn (OTCMKTS: CYDY) Bolts Higher On Mexican Approval Chatter

  Yesterday CytoDyn Inc. (OTCMKTS: CYDY) moved up 27% on the completion of a Memorandum of Understanding with the NIH of Mexico to...